Get the Stockscreener App
35.96
1.78%
+0.63
After Hours:
36.05
0.09
+0.25%
Revolution Medicines Inc stock is currently priced at $35.96, with a 24-hour trading volume of 1.21M.
It has seen a +1.78% increased in the last 24 hours and a +19.87% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $35.28 pivot point. If it approaches the $36.43 resistance level, significant changes may occur.
Previous Close:
$35.33
Open:
$35.38
24h Volume:
1.21M
Market Cap:
$5.92B
Revenue:
$29.52M
Net Income/Loss:
$-436.37M
P/E Ratio:
-11.03
EPS:
-3.26
Net Cash Flow:
$-358.30M
1W Performance:
+2.98%
1M Performance:
+19.87%
6M Performance:
+80.61%
1Y Performance:
+58.48%
1D Range:
$34.65
$36.36
52W Range:
$15.44
$38.73
Revolution Medicines Inc Stock (RVMD) Company Profile
Name
Revolution Medicines Inc
Sector
Industry
Phone
650-481-6801
Address
700 Saginaw Drive, Redwood City, CA
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-04-24 | Initiated | Wedbush | Outperform |
| Nov-16-23 | Initiated | Raymond James | Outperform |
| Feb-28-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-14-22 | Initiated | Needham | Buy |
| Oct-21-22 | Initiated | Oppenheimer | Outperform |
| May-20-22 | Initiated | BofA Securities | Neutral |
| Mar-01-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Aug-12-21 | Downgrade | Goldman | Buy → Neutral |
| May-18-21 | Initiated | Goldman | Buy |
| May-21-20 | Initiated | H.C. Wainwright | Buy |
| Mar-09-20 | Initiated | Cowen | Outperform |
| Mar-09-20 | Initiated | Guggenheim | Buy |
| Mar-09-20 | Initiated | JP Morgan | Neutral |
View All
Revolution Medicines Inc Stock (RVMD) Latest News
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Top 3 Health Care Stocks That May Collapse In Q2
Benzinga
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
GlobeNewswire Inc.
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
GlobeNewswire Inc.
Revolution Medicines to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Revolution Medicines Inc Stock (RVMD) Financials Data
Revolution Medicines Inc (RVMD) Revenue 2024
RVMD reported a revenue (TTM) of $29.52 million for the quarter ending June 30, 2023, a +8.33% rise year-over-year.
Revolution Medicines Inc (RVMD) Net Income 2024
RVMD net income (TTM) was -$436.37 million for the quarter ending December 31, 2023, a -75.46% decrease year-over-year.
Revolution Medicines Inc (RVMD) Cash Flow 2024
RVMD recorded a free cash flow (TTM) of -$358.30 million for the quarter ending December 31, 2023, a -52.33% decrease year-over-year.
Revolution Medicines Inc (RVMD) Earnings per Share 2024
RVMD earnings per share (TTM) was -$3.84 for the quarter ending December 31, 2023, a -23.87% decline year-over-year.
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
1.53%
3.38%
Cap:
|
Volume (24h):